Published on: Mar 3, 2016
Transcripts - Naresh ppt
Formulation and in vitro characterisation of cefpodoxime proxetil gastroretentive microballoons SUBMITTED BY: Y.NARESH I M.PHARM INDUSTRIAL PHARMACYSUBMITTED TO:Dr.H.G.SHIVA KUMARMr.HEMANT KUMAR YADAVDEPT OF PHARMACEUTICS
• Many attempts have been made to develop sustained-release preparations with extended clinical effects and reduced dosing frequency by oral delivery.• In order to develop an oral drug delivery systems, it is necessary to optimize both the release rate of the drug and the residence time of the system within the gastrointestinal tract.• Hollow microspheres or microballoons systems allow prolonged residence time of dosage forms in the stomach and achievement of constant plasma levels.
• Cefpodoxime proxetil (CP) is a prodrug of the third generation cephalosporins, which is broad-spectrum antibiotic and is administered orally.• In human, the absolute bioavailability of cefpodoxime proxetil administered as a 130mg tablet (equivalent to 100mg of cefpodoxime) is about 50% .• Reported studies have pointed possible reasons for low bioavailability as: low solubility, typical gelation behavior of CP particularly in acidic environments , and preabsorption of luminal metabolism into cefpodoxime acid by the action of digestive enzymes .
• It has been reported that the absorption of cefpodoxime proxetil is optimum at low pH.• The objective of the present work was to improve the bioavailability of cefpodoxime proxetil by formulating gastroretentive microballoons (hollow microspheres) in order to sustain the drug release .• MATERIALS AND METHODS:• Materials :• Cefpodoxime proxetil, HPMC, Ethyl cellulose and tween 80 , Ethanol ,Dicholoromethane
Methods: preparation of micro balloons• Microballoons (hollow microspheres) were prepared by the solvent evaporation technique.• Cefpodoxime proxetil (130mg), HPMC and EC (1:1) were dissolved in a mixture of alcohol and dichloromethane (1:1) at room temperature.• The resulting solution was poured into 250 ml of distilled water containing 0.01%(v/v) Tween 80, maintained at room temperature.• It is stirred at different agitation speed for 20 min to allow the volatile solvent to evaporate.• The microballoons formed were filtered, washed with water and dried.
Drug loading(DL), incorporation Efficiency (IE), and percentage yield:• To determine the incorporation efficiency microballoons (30mg) were thoroughly triturated and suspended in a minimal amount of alcohol,• suitably diluted with 0.1 N HCl (pH1.2) and filtered to separate shell fragments.• Amount of cefpodoxime proxetil (drug content/drug loading)was analyzed spectrophotometrically at 263 nm.• The equations are• %IE=calculated drug conc * 100 theorotical drug content
• DL=mass of the drug in microballoons * 100 mass of the recovered microballoonsInvitro drug release:• A USP paddle apparatus using 900 ml of 0.1 N HCl (pH 1.2) maintained at 37―0.5 °C with agitation speed of 75 rpm was used to study in vitro drug release.• Samples were withdrawn at interval of 2 hrs and analyzed spectrophotometrically at 263 nm.Buoyancy test:• Microballoons (0.3g) were spread over the surface of a USP (type II) dissolution apparatus with 900 ml of simulated gastric fluid(pH 1.2).
• The medium was agitated with a paddle rotating at 75 rpm for 12 hrs.• The floating and the settled portions of microballoons were recovered separately.• The microballoons were dried and weighed.• Buoyancy percentage was calculated as the ratio of the mass of the microballoons that remained floating and the total mass of the microballoons.Differential scanning colorimetry:• Thermal analysis was carried out using a DSC• Samples were placed in aluminum pans and heated at a scanning scanning rate of 5°C/min from 30 to 400°C.• Four samples i.e. pure cefpodoxime proxetil, pure HPMC, pure EC and cefpodoxime proxetil-loaded microballoons of
• of HPMC and EC were analysed. Results and discussionsPreparation and optimisation of microballoons:• The yield of microballoons was a function of diffusion of solvents in the organic phase into aqueous phase.• It has been reported that when the rate of the diffusion rate of solvent out of emulsion droplet is too slow, microspheres coalesced together.• Conversely, when the diffusion of solvent is too fast, the solvent may diffuse into the aqueous phase before stable emulsion droplets are developed,causing aggregation of embryonic microsphere droplets.
• From the results of this study it was found that average particle size and wall thickness of microballoons increased by increase in the polymer concentration as it is apparent from observations of formulations P1 to P4 having average particle size in the range of 54.23+2.78-95.66+2.19 µm.• This may be attributed to increased viscosity of medium at higher polymer concentration resulting in enhanced interfacial tension.• Shearing efficiency was also diminished at higher viscosities which results in the formation of larger particles.
• The temperature of the dispersing medium was animportant factor in the formation of microballoons,because it controls the rate of evaporation of thesolvents (Table1).• At lower temperature (8-10°C),the prepared microballoons had irregularly shaped surface morphology and the shell was translucent due to slow rate of diffussion of ethanol.• At higher temperatures, the shell of the microballoons was very thin and some of them were broken (formulation P16) which might be due to the faster diffusion of alcohol of the droplet into aqueous phase.
Scanning electron micrograph ofmicroballoons. A. Outer surface ofmicroballoons, B. Inner surface of a broken halfof a microballoon
• So optimum temperature has to be maintained for microballoons with good floating properties.• Characterisation of microballoons:• Results indicate that proportion of polymers in formulation was the key factor governing release of drug from microballoons.• As the concentration of polymer increased, there was an increased in diffusional path length. This may decrease the overall drug release from the polymer matrix.• Formulation comprised of EC in higher proportion exhibited much retarded drug release as compared to HPMC formulations (Figs 2A and 2B).• It is apparent that the drug release, from microballoons prepared at high temperatures, was slightly higher by virtue of thin shell of microballoons.
• The microballoons were spread over the surface of simulated gastric fluid (pH 1.2).the floating and the settled portions of microballoons were recovered separately.• It was obvious from results that most of the prepared microballoons remained floating for longer than 12 hrs thereby releasing the drug in dissolution media in sustained manner(Table1).• The result also showed a tendency that the larger the particle size ,the longer the floating time.• DSC thermogram of the cefpodoxime proxetil loadedmicroballoons revealed that the drug existed in the amorphous state in the shell of microballoons,
• Which indicates the absence of interactions between drug and polymers under study.• CONCLUSION:• The microballoons so prepared will remain buoyant On surface of gastric fluid releasing cefpodoxime proxetil in sustained fashion.• Inferences drawn from in vitro studies suggest that microballoons may prove as potential delivery system for cefpodoxime proxetil by improving bioavailability in comparison to conventional dosage form.
REFERENCE:DARU vol 19 , No 1 2011.